La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function

Identifieur interne : 000F63 ( Main/Exploration ); précédent : 000F62; suivant : 000F64

Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function

Auteurs : Alex A. Macdonald [Canada] ; Oury Monchi [Canada] ; Ken N. Seergobin [Canada] ; Hooman Ganjavi [Canada] ; Ruzbeh Tamjeedi [Canada] ; Penny A. Macdonald [Canada]

Source :

RBID : ISTEX:8B6C8EC007D61F4AF26978C2D0CDEB151CF8D1CA

English descriptors

Abstract

We investigated the hypothesis that variation in endogenous dopamine (DA) across brain regions explains dissimilar effects of dopaminergic therapy on aspects of cognition in early Parkinson's disease (PD). Extensive degeneration of DA‐producing cells in the substantia nigra cause dorsal striatum (DS) DA deficiency and movement abnormalities. Particularly in early PD, this contrasts with relative sparing of the dopaminergic cells of the ventral tegmental area (VTA). The hypothesis predicts that DS‐mediated cognitive functions are deficient at baseline and improved by DA replacement, whereas functions depending upon VTA‐innervated brain regions are normal off medication and worsen with treatment. The latter pattern presumably owes to overdose of relatively DA‐replete VTA‐supplied brain regions with medication levels titrated to DS‐mediated motor symptoms. As PD progresses, however, VTA degeneration increases. Impairment in cognitive operations performed by VTA‐innervated brain regions, such as the ventral striatum (VS), is expected. We compared the performance of early and late PD patients, on and off dopaminergic medication, relative to age‐matched controls, on reward learning, previously shown to implicate the VS. As expected, in early PD, stimulus‐reward learning was normal off medication, but worsened with DA replacement. At more advanced disease stages, PD patients learned stimulus‐reward contingencies more poorly than controls and early PD patients off medication. Furthermore, dopaminergic medication did not worsen reward learning in late PD patients, in line with the dopamine overdose hypothesis. Unlike its effect on DS‐mediated functions, however, DA‐replacement therapy did not improve reward learning in late PD patients. © 2012 Movement Disorder Society

Url:
DOI: 10.1002/mds.25152


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function</title>
<author>
<name sortKey="Macdonald, Alex A" sort="Macdonald, Alex A" uniqKey="Macdonald A" first="Alex A." last="Macdonald">Alex A. Macdonald</name>
</author>
<author>
<name sortKey="Monchi, Oury" sort="Monchi, Oury" uniqKey="Monchi O" first="Oury" last="Monchi">Oury Monchi</name>
</author>
<author>
<name sortKey="Seergobin, Ken N" sort="Seergobin, Ken N" uniqKey="Seergobin K" first="Ken N." last="Seergobin">Ken N. Seergobin</name>
</author>
<author>
<name sortKey="Ganjavi, Hooman" sort="Ganjavi, Hooman" uniqKey="Ganjavi H" first="Hooman" last="Ganjavi">Hooman Ganjavi</name>
</author>
<author>
<name sortKey="Tamjeedi, Ruzbeh" sort="Tamjeedi, Ruzbeh" uniqKey="Tamjeedi R" first="Ruzbeh" last="Tamjeedi">Ruzbeh Tamjeedi</name>
</author>
<author>
<name sortKey="Macdonald, Penny A" sort="Macdonald, Penny A" uniqKey="Macdonald P" first="Penny A." last="Macdonald">Penny A. Macdonald</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:8B6C8EC007D61F4AF26978C2D0CDEB151CF8D1CA</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1002/mds.25152</idno>
<idno type="url">https://api-v5.istex.fr/document/8B6C8EC007D61F4AF26978C2D0CDEB151CF8D1CA/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000E17</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000E17</idno>
<idno type="wicri:Area/Istex/Curation">000E17</idno>
<idno type="wicri:Area/Istex/Checkpoint">000081</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000081</idno>
<idno type="wicri:doubleKey">0885-3185:2013:Macdonald A:parkinson:s:disease</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:23165957</idno>
<idno type="wicri:Area/PubMed/Corpus">000960</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000960</idno>
<idno type="wicri:Area/PubMed/Curation">000960</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000960</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000960</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000960</idno>
<idno type="wicri:Area/Ncbi/Merge">001314</idno>
<idno type="wicri:Area/Ncbi/Curation">001314</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001314</idno>
<idno type="wicri:Area/Main/Merge">000F75</idno>
<idno type="wicri:Area/Main/Curation">000F63</idno>
<idno type="wicri:Area/Main/Exploration">000F63</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function</title>
<author>
<name sortKey="Macdonald, Alex A" sort="Macdonald, Alex A" uniqKey="Macdonald A" first="Alex A." last="Macdonald">Alex A. Macdonald</name>
<affiliation wicri:level="4">
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Psychology, McGill University, Quebec, Montreal</wicri:regionArea>
<placeName>
<settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
<settlement type="city">Montréal</settlement>
</placeName>
<orgName type="university">Université McGill</orgName>
</affiliation>
</author>
<author>
<name sortKey="Monchi, Oury" sort="Monchi, Oury" uniqKey="Monchi O" first="Oury" last="Monchi">Oury Monchi</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Functional Neuroimaging Unit, Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec</wicri:regionArea>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3">
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Radiology, University of Montreal, Quebec, Montreal</wicri:regionArea>
<placeName>
<settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Seergobin, Ken N" sort="Seergobin, Ken N" uniqKey="Seergobin K" first="Ken N." last="Seergobin">Ken N. Seergobin</name>
<affiliation wicri:level="4">
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Centre for Biological Timing and Cognition, University of Toronto, Ontario, Toronto</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName>
<settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Ganjavi, Hooman" sort="Ganjavi, Hooman" uniqKey="Ganjavi H" first="Hooman" last="Ganjavi">Hooman Ganjavi</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Psychiatry, The University of Western Ontario, Ontario, London</wicri:regionArea>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Tamjeedi, Ruzbeh" sort="Tamjeedi, Ruzbeh" uniqKey="Tamjeedi R" first="Ruzbeh" last="Tamjeedi">Ruzbeh Tamjeedi</name>
<affiliation wicri:level="4">
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Philosophy, McGill University, Quebec, Montreal</wicri:regionArea>
<placeName>
<settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
<settlement type="city">Montréal</settlement>
</placeName>
<orgName type="university">Université McGill</orgName>
</affiliation>
</author>
<author>
<name sortKey="Macdonald, Penny A" sort="Macdonald, Penny A" uniqKey="Macdonald P" first="Penny A." last="Macdonald">Penny A. Macdonald</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Canada</country>
<wicri:regionArea>The Brain and Mind Institute, The University of Western Ontario, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3">
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Clinical Neurological Sciences, The University of Western Ontario, Ontario, London</wicri:regionArea>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
<affiliation></affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov Disord</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint>
<publisher>Blackwell Publishing Ltd</publisher>
<date type="published" when="2013-02">2013-02</date>
<biblScope unit="volume">28</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="153">153</biblScope>
<biblScope unit="page" to="160">160</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">8B6C8EC007D61F4AF26978C2D0CDEB151CF8D1CA</idno>
<idno type="DOI">10.1002/mds.25152</idno>
<idno type="ArticleID">MDS25152</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Age Factors</term>
<term>Age of Onset</term>
<term>Aged</term>
<term>Analysis of Variance</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Basal Ganglia (physiopathology)</term>
<term>Computers</term>
<term>Dopamine (physiology)</term>
<term>Dopamine Agents (administration & dosage)</term>
<term>Dopamine Agents (adverse effects)</term>
<term>Dopamine Agents (therapeutic use)</term>
<term>Educational Status</term>
<term>Female</term>
<term>Humans</term>
<term>Learning</term>
<term>Magnetic Resonance Imaging</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neuropsychological Tests</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Photic Stimulation</term>
<term>Psychomotor Performance (physiology)</term>
<term>Reward</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Antiparkinson Agents</term>
<term>Dopamine Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en">
<term>Antiparkinson Agents</term>
<term>Dopamine Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en">
<term>Dopamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Antiparkinson Agents</term>
<term>Dopamine Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Psychomotor Performance</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en">
<term>Basal Ganglia</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Age Factors</term>
<term>Age of Onset</term>
<term>Aged</term>
<term>Analysis of Variance</term>
<term>Computers</term>
<term>Educational Status</term>
<term>Female</term>
<term>Humans</term>
<term>Learning</term>
<term>Magnetic Resonance Imaging</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neuropsychological Tests</term>
<term>Photic Stimulation</term>
<term>Reward</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract">We investigated the hypothesis that variation in endogenous dopamine (DA) across brain regions explains dissimilar effects of dopaminergic therapy on aspects of cognition in early Parkinson's disease (PD). Extensive degeneration of DA‐producing cells in the substantia nigra cause dorsal striatum (DS) DA deficiency and movement abnormalities. Particularly in early PD, this contrasts with relative sparing of the dopaminergic cells of the ventral tegmental area (VTA). The hypothesis predicts that DS‐mediated cognitive functions are deficient at baseline and improved by DA replacement, whereas functions depending upon VTA‐innervated brain regions are normal off medication and worsen with treatment. The latter pattern presumably owes to overdose of relatively DA‐replete VTA‐supplied brain regions with medication levels titrated to DS‐mediated motor symptoms. As PD progresses, however, VTA degeneration increases. Impairment in cognitive operations performed by VTA‐innervated brain regions, such as the ventral striatum (VS), is expected. We compared the performance of early and late PD patients, on and off dopaminergic medication, relative to age‐matched controls, on reward learning, previously shown to implicate the VS. As expected, in early PD, stimulus‐reward learning was normal off medication, but worsened with DA replacement. At more advanced disease stages, PD patients learned stimulus‐reward contingencies more poorly than controls and early PD patients off medication. Furthermore, dopaminergic medication did not worsen reward learning in late PD patients, in line with the dopamine overdose hypothesis. Unlike its effect on DS‐mediated functions, however, DA‐replacement therapy did not improve reward learning in late PD patients. © 2012 Movement Disorder Society</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Canada</li>
</country>
<region>
<li>Angleterre</li>
<li>Grand Londres</li>
<li>Ontario</li>
<li>Québec</li>
</region>
<settlement>
<li>Londres</li>
<li>Montréal</li>
<li>Toronto</li>
</settlement>
<orgName>
<li>Université McGill</li>
<li>Université de Toronto</li>
</orgName>
</list>
<tree>
<country name="Canada">
<region name="Québec">
<name sortKey="Macdonald, Alex A" sort="Macdonald, Alex A" uniqKey="Macdonald A" first="Alex A." last="Macdonald">Alex A. Macdonald</name>
</region>
<name sortKey="Ganjavi, Hooman" sort="Ganjavi, Hooman" uniqKey="Ganjavi H" first="Hooman" last="Ganjavi">Hooman Ganjavi</name>
<name sortKey="Macdonald, Penny A" sort="Macdonald, Penny A" uniqKey="Macdonald P" first="Penny A." last="Macdonald">Penny A. Macdonald</name>
<name sortKey="Macdonald, Penny A" sort="Macdonald, Penny A" uniqKey="Macdonald P" first="Penny A." last="Macdonald">Penny A. Macdonald</name>
<name sortKey="Monchi, Oury" sort="Monchi, Oury" uniqKey="Monchi O" first="Oury" last="Monchi">Oury Monchi</name>
<name sortKey="Monchi, Oury" sort="Monchi, Oury" uniqKey="Monchi O" first="Oury" last="Monchi">Oury Monchi</name>
<name sortKey="Seergobin, Ken N" sort="Seergobin, Ken N" uniqKey="Seergobin K" first="Ken N." last="Seergobin">Ken N. Seergobin</name>
<name sortKey="Tamjeedi, Ruzbeh" sort="Tamjeedi, Ruzbeh" uniqKey="Tamjeedi R" first="Ruzbeh" last="Tamjeedi">Ruzbeh Tamjeedi</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F63 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F63 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:8B6C8EC007D61F4AF26978C2D0CDEB151CF8D1CA
   |texte=   Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022